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ARTICLE OPEN ACCESS
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Description of a new variant of the glutamine-fructose-6-phosphate transaminase 1 (GFPT1)
gene causing congenital myasthenic syndrome (CMS) in 3 children from 2 unrelated families.
Methods
Muscle biopsies, EMG, and whole-exome sequencing were performed.
Results
All 3 patients presented with congenital hypotonia, muscle weakness, respiratory insufficiency,
head lag, areflexia, and gastrointestinal dysfunction. Genetic analysis identified a homozygous
frameshift insertion in the GFPT1 gene (NM_001244710.1: c.686dupC; p.Arg230Ter) that was
shared by all 3 patients. In one of the patients, inheritance of the variant was through uniparental
disomy (UPD) with maternal origin. Repetitive nerve stimulation and single-fiber EMG was
consistent with the clinical diagnosis of CMS with a postjunctional defect. Ultrastructural eval-
uation of the muscle biopsy from one of the patients showed extremely attenuated postsynaptic
folds at neuromuscular junctions and extensive autophagic vacuolar pathology.
Conclusions
These results expand on the spectrum of known loss-of-function GFPT1mutations in CMS12
and in one family demonstrate a novel mode of inheritance due to UPD.
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Congenital myasthenic syndrome (CMS) is a genetically and
clinically heterogeneous group of disorders with compro-
mised neuromuscular transmission. Common underlying
symptoms are fatigable skeletal muscle weakness confined to
the ocular, bulbar, or limb-girdle muscles.1 Classification of
CMS is based on inheritance pattern and localization of
defects at the neuromuscular junction (NMJ).1,2 To date, over
30 genes have been identified to cause CMS, which are
functionally critical for the development and maintenance of
NMJ.3,4 Mutations in genes involved in the N-linked glyco-
sylation pathway have also been identified to cause CMS.
Genetic linkage analysis and whole-exome sequencing (WES)
experiments have identified biallelic mutations in the gene
encoding glutamine-fructose-6-phosphate transaminase 1
(GFPT1, Online Mendelian Inheritance in Man [OMIM]:
138292) as the cause of CMS type 12 (OMIM:610524).
GFPT1 enzyme converts fructose-6-phosphate to glucos-
amine-6-phosphate through a rate-limiting transamidase re-
action that regulates the biosynthesis of N-acetylglucosamine
and protein glycosylation.2,5 Most of the biallelicGFPT1 gene
mutations that cause CMS12 are missense, nonsense, or
frameshift with protein truncation, and also a recurrent 39-
untranslated region mutation has also been reported.2,5,6
Patients with GFPT1 mutation display characteristic symp-
toms such as limb-girdle weakness and tubular aggregates
(TAs) in skeletal muscle fibers.5 Patients also show evidence
of decremental response to repetitive nerve stimulation
(RNS), indicating NMJ dysfunction.7 In this study, we pres-
ent clinical, neurophysiologic, histopathologic, and genetic
findings in 2 unrelated families with 3 affected children di-
agnosed with CMS12 who share the same loss-of-function
GFPT1 variant. This report expands on current knowledge of
the effects of pathogenic GFPT1 variants.
Methods
Standard protocol approvals, registrations,
and patient consents
Family Awas enrolled in the research protocol at the Center for
Rare Childhood Disorders (C4RCD). The protocol was
reviewed and approved by the Western Institutional Review
Board (Protocol #20120789). Informed consent for sequenc-
ing and data usage was obtained from each participant or their
guardian for children younger than the age of 18. Patient A1
had clinical evaluation at C4RCD. Patients from family B were
evaluated at the Department of Neurology, The University of
California, Los Angeles (patient B1), and Providence Medical
Group (patient B2).
Whole-exome sequencing
Patient A1 had trio WES and analysis at TGen. Sequence data
were analyzed using in-house-developed pipeline that included
alignment, quality filtering, single nucleotide variant and indel
calling, copy number analysis, variant annotation, and filtering.8
The annotated variant list was filtered using genetic models
including de novo, homozygous recessive, compound hetero-
zygous, and X-linked. Candidate variants were prioritized based
on population frequency, in-silico predictions, and clinical phe-
notype. Candidate variants were validated by Sanger sequencing.
Patient B1 had clinical WES at The University of California,
Los Angeles Clinical Genomics Center as a singleton.9 Patient
B2 underwent targeted GFPT1 gene sequencing by Pacific
Biosciences.
Neurophysiologic studies
Nerve conduction, EMG, and repetitive stimulation studies
were performed on patient A1. Patient B1 had single fiber
EMG on the left extensor digitorum communis.
Data availability




Family A, patient A1
This is a 11-year-old Hispanic girl with severe muscle weakness
since birth. She was born at term by emergency C-section because
of fetal heart rate irregularities. She required bag-mask ventilation,
was electively intubated, and required mechanical ventilation. A
gastrostomy tube was placed at 1 month of age. Physical exami-
nation revealed severe hypotonia, weakness, decreased spontane-
ous movement, and areflexia. At 5 months of age, she
demonstrated severe head lag with hypotonia. Fluctuating
responses were seen with deep tendon reflexes. An examination at
2.5 years revealed significant diffuse hypotonia, severe muscle
weakness, facial diplegia, minimal to no movement of her
shoulders and proximal legs, flabby muscles, severe head lag, and
hyporeflexia. She had severe scoliosis, requiring the use of a neck
collar and thoracic brace. Based on her EMG findings (figure 1),
she was treated with pyridostigmine and had a partial response. At
3 years of age, she underwent tracheostomy and was treated with
3,4-diaminopyridine together with pyridostigmine. The addition
of 3,4-diaminopyridine did not result in significant clinical
Glossary
C4RCD = Center for Rare Childhood Disorders; CMS = congenital myasthenic syndrome; GFPT1 = glutamine-fructose-6-
phosphate transaminase 1; LCRH = long contiguous regions of homozygosity;NEB = nebulin;NMJ = neuromuscular junction;
RNS = repetitive nerve stimulation; SMA = spinal muscular atrophy; TA = tubular aggregate; UPD = uniparental disomy;
WES = whole-exome sequencing.
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improvement and was discontinued because of changes in her
ECG. There was no family history of muscle disorders, and both
parents were unaffected. Previous molecular testing included
a chromosomal microarray, which revealed 2 long contiguous
regions of homozygosity (LCRH) of 57.6, and 89.8 Mbases on
chromosome 2p21q11.2 and 2q22.1q36.3, respectively. Genetic
testing was negative for spinal muscular atrophy (SMA), Prader-
Willi syndrome, congenital myotonic dystrophy, and the genes
linked toCMSknownbefore year 2010 (table 1). Targeted testing
for SURF1, SCO1, SCO2, and COX10 mutations was negative.
Family B, patient B1
This is an 8-year-old boy of Mexican ancestry with congenital
hypotonia, low muscle bulk, dysphagia requiring gastrostomy
tube feeding, recurrent respiratory infections, and with a trache-
ostomy. He was born at 39 weeks gestation to a 34-year-old G9
P7 mother via vaginal delivery after an uncomplicated preg-
nancy. At initial evaluation, he was noted to be floppy, with
a sluggishly reactive left pupil. He eventually underwent gas-
trostomy tube placement and tracheostomy and needed me-
chanical ventilation. At 1 month, he was found to have bilateral
cryptorchidism, micrognathia, a high arched palate without ev-
idence of cleft, head lag, marked decrease in proximal tone, and
absent deep tendon reflexes. At 10 months of age, he weighed
3.6 kg and was bright and alert. There was minimal spontaneous
movement, minimal movement of the arms, and no movement
of the legs at all. He slipped through at the shoulders on vertical
suspension and had a severe head lag. Tone was slightly better in
Table 1 Variants associated with CMS and ruled out





NEB c.18660G>C p.Leu6220Phe Tolerated Benign Missense 0.02925 Comp het
B1 0/
1
NEB c.5696C>T p.Thr1899Ile Tolerated Probably
damaging
Missense 0.04445 Comp het
B1 0/
1






















SCN4A c.404T>C p.Met135Thr Tolerated Benign Missense 0.15 —
Abbreviations: CMS = congenital myasthenic syndrome; comp het = compound heterozygous; GT = genotype; HGNC = HUGO Gene Nomenclature
Committee; HGVS.c = Human Genome Variation Society coding DNA reference sequence position; HGVS.p = HGVS protein reference sequence position;
MAF = minor allele frequency; NEB = nebulin; SIFT = Sorting Intolerant from Tolerant.
Figure 1 Clinical neurophysiology
Decremental response on 3 Hz repetitive nerve stimulation of hand muscle of patient A showing a postjunctional neuromuscular deficit by postactivation
facilitation and then exhaustion; decrement of 13% at rest (A), 7% immediately after 30 seconds exercise (B), and 15% at 360 seconds after the exercise (C).
Stimulated (15 c/s) single-fiber EMG study on extensor digitorum communis muscle on patient B1 demonstrating a large jitter on the last unit (D).
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the legs than the arms. At the age of 2 years, he was able to
breathe on his own, requiring intermittent mechanical ventila-
tion during hospitalizations for respiratory infections. At the age
of 8 years, he wore a neck brace and thoracolumbosacral or-
thosis. He had a tracheostomy tube, ate pureed food by mouth,
and received supplemental nutrition by G-tube. The patient had
normal speech and intelligence and attended 2nd grade in
a special needs school. His medications included budesonide,
cholecalciferol, guar gum, levalbuterol, and docusate. He started
3,4-diamnopyridine at the age of 8 years, without benefit. Pre-
vious molecular testing included a normal karyotype, negative
testing for Prader-Willi, SMA, and congenital myotonic dystro-
phy. Enzymatic and metabolic assays for creatine kinase, thyroid
function, serum cortisol, plasma ammonia, quantitative amino
acid profile, very long chain fatty acids, pyruvate, lactate, and
acylcarnitine profile were all normal.
Family B, patient B2
This boy is the younger sibling of patient B1, and he died at the
age of 2 years. He was born at 37-1/2 weeks of gestation after
a pregnancy complicated by gestational diabetes and hyperten-
sion. He was intubated immediately after delivery and required
resuscitation with chest compression. In the neonatal intensive
care unit, he was started on a therapeutic hypothermia protocol
for presumed hypoxic-ischemic encephalopathy. On initial
evaluation, EEG was abnormal (presumably because of hypo-
thermia) but showed no evidence of seizures and improved after
rewarming. Echocardiogram and renal ultrasound were normal.
Head ultrasound revealed grade 1 germinal matrix hemorrhage,
and brain MRI showed left germinal matrix and intraventricular
hemorrhage. He had a broad nasal bridge, ptosis, micrognathia,
a tented upper lip, high and narrow palate, slightly wide set
nipples, and descended testes. He also had loose skin on his neck
and around his thighs. His torso appeared long, and there was
a limitation of elbow extension to approximately 150°, and he
had diffusely decreased muscle tone and absent tendon reflexes.




Nerve conduction studies at the age of 2 years revealed low
compound muscle action potentials, especially in the trapezius
and facial muscles. EMG showed rapid recruitment of motor
units suggestive of a myopathy. There was no spontaneous
activity in limb muscles. A 13% decremental response to 3 Hz
RNSwas seen only in the handmuscles and not in the trapezius
muscle. At the age of 6 years, the RNS revealed postactivation
facilitation and postexercise exhaustion suggestive of a post-
synaptic NMJ defect (figure 1, A–C).
Patient B1
At 10 months, a reproducible decrement of 18% was seen on
RNS of the left abductor pollicis brevis muscle. At the age of 6
years, RNS demonstrated a 14% decremental response of
abductor pollicis minimi and a 39% decremental response on
the trapezius. Radial nerve-stimulated single-fiber EMG of the
left extensor digitorum communis muscle demonstrated a dra-
matically increased variability of latency (jitter) in 11 pairs of
the 14 pairs tested, with an averagemean consecutive difference
value of 165.5 microseconds (normal <36.6) and blocking seen
in 8 pairs of 14 total tested, suggesting a disorder of neuro-
muscular transmission (figure 1D).
Muscle biopsy
Patient A1
A quadriceps muscle biopsy performed at 1 month of age was
nondiagnostic. No residual tissue was available for further
evaluation including electron microscopy after the genetic
diagnosis.
Patient B1
A left quadriceps muscle biopsy at the age of 1 month showed
a population of abnormally small muscle fibers that was sug-
gestive of a myopathy. No residual tissue was available for
further evaluation after genetic diagnosis.
Patient B2
Light microscopy and transmission electron microscopy
revealed a mild necrotizing myopathy with extensive auto-
phagic vacuolar pathology (figure 2A). Autophagic vacuoles
had sarcolemmal features in that acetylcholinesterase was lo-
calized at the surface of cytoplasmic vacuoles (figure 2B). Ex-
trusion of autophagic vacuoles from affected muscle fibers was
noted (figure 2C). Intramuscular nerve twigs seemed normal in
cryosections (not shown) and in electron micrographs (figure
2D). By contrast, NMJs had varying degrees of postsynaptic
fold attenuation (figure 2, E–H), whereas synaptic vesicles were
numerous within nerve terminals. Complete absence of NMJ
end plate folds was noted in association with some nerve ter-
minals (figure 2H). No TAs were observed.
Genetic findings
Patient A1
An average of 61X coverage was obtained in the trio exomes.
Previous chromosomal microarray data suggested that unipa-
rental disomy (UPD) of chromosome 2 and that pathogenic
homozygous variants on chromosome 2 may contribute to the
patient’s symptoms. Copy number and homozygosity analysis of
the exome data confirmed the copy neutral long contiguous
stretches of homozygosity reported by array comparative ge-
nomic hybridization (A 3). A homozygous, frameshift insertion
was discovered inGFPT1 at 2p13.3 (chr2:69581443insG; NM_
001244710.1:c.686dupC; p.Arg230Ter) (figure 3). This variant
is at the 59 end of exon 9, adjacent to the splice acceptor site of
the muscle/heart specific transcript (NM_001244710), and
results in the introduction of a termination codon. The variant
was observed in the mother as a heterozygous change, whereas
the father was a homozygous reference, suggesting UPD. These
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findings were independently confirmed by Sanger sequencing
and confirmed loss of the paternal chromosome 2 segment
(figure 4, A and B). This variant is observed in a single individual
(1/219894) as a heterozygous change in the gnomAD v2.1.1
database.10 In-silico predictions suggested that GFPT1 is in-
tolerant to loss-of function variation (Exome Aggregation
Consortium probability of being loss-of-function intolerant =
0.97). There are 10 GFPT1 variants in ClinVar, in patients with
CMS12, classified as pathogenic or likely pathogenic, which
include missense, stop gained, and frameshift indels (table 2).
Evaluation of the known genes associated with CMS revealed
that Patient A1 was heterozygous for variants in CHAT,MUSK,
RAPSN, and SCN4A that were ruled out because of insufficient
evidence for pathogenicity using American College of Medical
Genetics criteria.11 There were no additional candidates outside
the region of LCRH found to correlate with the patient’s
symptoms.
Patient B1
An average of 154X coverage was obtained for this singleton
WES. Variants of uncertain clinical significance were iden-
tified in nebulin (NEB), SH3T2C, POLG, and GFPT1 genes.
After clinical correlation, potential compound heterozygous
variants in the gene (NEB, OMIM:161650) were reported.9
Figure 2 Muscle biopsy pathology of patient B2
The cryosection H&E image (A) shows increased
variation in fiber size and a mild degree of re-
generation (arrow), suggesting that the patient
has a mild, necrotizing myopathy. AChE enzyme
histochemistry (B) highlights numerous cyto-
plasmic autophagic vacuoles with sarcolemmal
features (arrows). Extensive autophagy is con-
firmed by electron microscopy (C). av occupy
most of the intracellular space of the muscle fi-
ber in the upper portion of the micrograph. Only
rare sarcomeres are present, as noted by 2 Z-
lines (z) in this image. Extrusion of autophagic
vacuoles (E) is evident at the surface of this
muscle fiber. Intramuscular nerve twigs appear
normal (D). Two of numerous NMJs observed in
the biopsy are illustrated in panels (E–H). There
are varying degrees of postsynaptic fold attenu-
ation (arrows), milder in panels E and G and
complete loss of NMJ endplate folds in panels F
and H. Nerve terminals contain numerous sv.
Portions of muscle fiber nuclei are present along
the top of panels E, F, and H (n). AChE = acetyl-
cholinesterase; av = autophagic vacuoles; H&E =
hematoxylin & eosin; NMJ = neuromuscular
junction; sv = synaptic vesicles.
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NEB is associated with autosomal recessive nemaline my-
opathy type 2 (OMIM: 256030) which carries similar fea-
tures to CMS but is also associated with nemaline rods.12
Parents were not available to determine phase of the 2 NEB
variants. Reanalysis of exome data was requested, and the
GFPT1 p. Arg230Ter variant was reclassified as likely
pathogenic. Other CMS-related variants were also identified
in CHRND and LAMB2 but were ruled out per American
College of Medical Genetics guidelines.
Patient B2
Sequencing in the patient and his parents using congenital
myopathy gene panel testing (Pacific Biosciences, Menlo
Park, CA) identified the same p.Arg230Ter homozygous
variant in B2 and demonstrated that both parents were
heterozygous.
Discussion
We report the first case of maternal UPD of chromosome 2 in
CMS and with a novel loss-of-function variant in GFPT1 and
provide support for pathogenicity of this variant by describing
another family with CMS sharing the same variant. These 3
patients, from 2 unrelated families, with similar clinical phe-
notypes further expand the clinical spectrum of CMS12.
Other CMS-related genetic variants were excluded in these
families (table 1). From a clinical perspective, all patients
presented with the classic clinical features of CSM12,
including hypotonia, general muscle weakness, little to no
movement of shoulders and proximal legs, feeding difficulty,
and EMGdecrement in 2 of the 3 patients (table 3). However,
they also share symptoms not commonly observed in CMS12.
All of them manifested with respiratory insufficiency that re-
quired ventilator support at one point which is mostly asso-
ciated with DOK7 or RAPSN deficiency.13 Although CMS12
usually manifests within the first decade of life, only a few
cases have been reported with congenital onset.5 Here, all 3
patients manifested with clinical symptoms at birth. In fact, 2
patients previously reported with early onset of disease carried
splice altering variants at the muscle specific exon 9 junction
and predicted biallelic loss of GFPT1, suggesting that loss-of-
function variants confined to the muscle and heart-specific
transcript adversely affects muscle fiber integrity and may
result in earlier onset and a more severe clinical course.14,15
Although the addition of 3,4-diaminopyridine to pyr-
idostigmine treatment resulted in a positive response in one of
the patients with GFPT1 mutation (B2), it did not improve
symptoms in Patient A1 or B1, indicating heterogeneity in
response to the drug treatment. Selcen et al.14, reported a fe-
male patient with nonambulatory status, requiring respiratory
support and a G-tube, harboring a nonsense and a splice-
altering variant; her muscle biopsy demonstrated autophagic
vacuolar pathology and attenuation of NMJ end plate folds,
similar to the findings in themost severely affected (patient B2)
of our children and absence of a;70 kd glycoprotein. Muscle
biopsies from many of the reported CMS12 cases have shown
Figure 3 GFPT1 gene and previously reported, ClinVar pathogenic and likely pathogenic variants in CMS12
BAF plot fromWES of patient A1 (top) demonstrates long continuous regions of homozygosity (blue dots with BAF;1 or BAF;0) that overlaps with previous
array CGH data (green horizontal bars). Red, vertical bar at 2p13.3 on the cytoband indicates the position ofGFPT1 genewithin the LCRH. Below the cytoband,
domain structure of GFPT1 and ClinVar pathogenic and likely pathogenic mutations in relation to GFPT1 domains of NM_001244710 and to p.Arg230*
(underlined) identified in this study. Variants are colored based on their functional impact (green = missense, black = frameshift, red = nonsense, and blue =
splice). BAF =B allele frequency; CGH= comparative genomic hybridization;GFPT1 = glutamine-fructose-6-phosphate transaminase 1; LCRH= long contiguous
regions of homozygosity; SIS = sugar isomerase domain; WES = whole-exome sequencing.
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TAs, leading to the term congenital myasthenic syndrome with
tubular aggregates5 None of our patients demonstrated TAs on
histopathologic studies.
The p.Arg230Ter variant has not been described before in
patients with CMS12 and is predicted to result in loss of
GFPT1 protein in muscle and heart cells.16 Although this
Table 2 Clinvar pathogenic GFPT1 variants in CMS12 based on ClinVar release date April 29, 2020
HGVS.c HGVS.p Pubmed ID Clinvar variant ID
NM_002056.4:c.1051+1G>A a 23794683 540351
NM_002056.4:c.1042G>T p.Asp348Tyr 21310273 29738
NM_002056.4:c.928C>T p.Gln310Ter 28492532 570975
NM_001244710.2:c.964C>T p.Arg322Ter 23794683 859066
NM_001244710.1:c.719G>A p.Trp240Ter 21310273 29737
NM_002056.4:c.621del p.Leu207_Leu208insTer 21310273 29740
NM_002056.4:c.452C>A p.Thr151Lys 30635494 631478
NM_001244710.1:c.331C>T p.Arg111Cys 21310273|8664562 29735
NM_001244710.1:c.223dupA p.Gln76Alafs11a 21310273 29736
NM_002056.3:c.197_201delTTAAG p.Val66Glyfs4a 28492532 583230
NM_001244710.1:c.43A>G p.Thr15Ala 12467753|12467753 29739
NM_002056.4:c.41G>T p.Arg14Leu 30635494 631477
NM_001244710.1:c.686-2A>G a 28464723|23794683 540353
Abbreviations: CMS = congenital myasthenic syndrome; GFPT1 = glutamine-fructose-6-phosphate transaminase 1.
a Splice mutation.
Figure 4 Sequence traces of p.Arg230*
(A) Sanger sequencing-confirmed exome se-
quencing findings for members of family A and
for patient B1 with the red arrow indicating the
frameshift insertion. Mother is heterozygous in-
dicated by the overlapping peaks, whereas fa-
ther was homozygous reference. (B) PacBio
sequence traces showing patient B2 homozy-
gosity. GFPT1 = glutamine-fructose-6-phosphate
transaminase 1.
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genetic variant is shared among all 3 of the described children,
the variation in severity and spectrum of symptoms suggest
pathophysiologic complexity. To the best of our knowledge,
patient A1 is the first instance of maternal UPD of chromo-
some 2, homozygosity for the GFPT1 nonsense mutation lo-
cated within the UPD region, inherited from amother who was
heterozygous for the pathogenic GFPT1 variant. Glycosylation
deficiency is one of the causes of CMS, and mutations have
been identified in several glycosylation pathway genes in-
cluding DPAGT1, ALG2, ALG14, and GFPT1.5,17,18 The exact
mechanism by which glycosylation deficiency causes the NMJ
defect is still unclear. Loss of GFPT1 protein can result in
abnormal glycosylation in muscle cells, reduced acetylcholine
receptor cell surface expression, and abnormal sialylation of
transmembrane muscle proteins.14,19,20 Electrophysiologic
studies in one of our children who had UPD and predicted loss
of function of the GFPT1, suggesting a postsynaptic NMJ
defect. Reduction in GFPT1 induces structural changes in the
end plate characterized by loss of junctional folds and
denervation-reinnervation process affecting NMJ.19 However,
the molecular consequences of absence of the ubiquitously
expressed GFPT1 protein is not fully understood. This report
expands the clinical, genetic, histologic and electrophysiologic
spectrum of GFPT1 gene mutations related CMS12.
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APGAR 5,6,6 1,6,7 1,2,5
Generalized muscle weakness b b b
Ambulation a a b a
Hypotonia b b b a b
Head lag/muscle weakness b b b b
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Prominent neck flexor
weakness
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Cardiovascular irregularities b a
Abbreviations: APGRA = appearance, pulse, grimace, activity, and respiration; HGVS.c = Human Genome Variation Society coding DNA reference sequence
position.
a Not observed. Empty cells indicate no information.
b Observed.
8 Neurology: Genetics | Volume 6, Number 4 | August 2020 Neurology.org/NG
disclosures. P.B. Shieh, S.P. Yang, S.A. Moore, H. Lee, N.
Belnap, C. Balak, A.L. Siniard, M. Russell, R. Richholt, M.D.
Both, A.M. Claasen, I. Schrauwen, S.F. Nelson, M.J. Huentel-
man, D.W. Craig, K. Sivakumar, V. Narayanan, and S. Ran-
gasamy report no disclosures. Go toNeurology.org/NG for full
disclosures.
Publication history













Jonida Krate, BS Translational
Genomics Research
Institute



















































































































































































Data analysis and data
interpretation
Emilie Douine, MS University of
California Los
Angeles







Data analysis and data
interpretation
Celeste Eno, PhD University of
California Los
Angeles







Data analysis and data
interpretation
Continued
Neurology.org/NG Neurology: Genetics | Volume 6, Number 4 | August 2020 9
References
1. de Souza PVS, Batistella GN de R, Lino VC, de Rezende Pinto WBV, Annes M,
Oliveira ASB. Clinical and genetic basis of congenital myasthenic syndromes. Arq
Neuro-Psiquiatr 2016;74:750–760.
2. Senderek J, Müller JS, Dusl M, et al. Hexosamine biosynthetic pathway mutations
cause neuromuscular transmission defect. Am J Hum Genet 2011;88:162–172.
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15. Yiş U, Becker K, Kurul SH, et al. Genetic landscape of congenital myasthenic syn-
dromes from Turkey: novel mutations and clinical insights. J Child Neurol 2017;32:
759–765.
16. DeHaven JE, Robinson KA, Nelson BA, Buse MG. A novel variant of glutamine:
fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in
striated muscle. Diabetes Am Diabetes Assoc 2001;50:2419–2424.
17. Cossins J, Belaya K, Hicks D, et al. Congenital myasthenic syndromes due to muta-
tions in ALG2and ALG14. Brain 2013;136:944–956.
18. Klein A, Robb S, Rushing E, Liu WW, Belaya K, Beeson D. Congenital myasthenic
syndrome caused by mutations in DPAGT. Neuromuscular disorders. Neuromuscul
Disord 2015;25:253–256.
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